Tertiary Nav - Press Releases Press ReleasesMedia Statements Press Releases Items Per Page 102550 News Category Business & FinancialCitizenshipEarningsMedia StatementProduct NewsRecognitionRegulatoryScience & Innovation Year None2021202020192018201720162015201420132012201120102009200820072006 Date Title 11/29/19 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 11/14/19 Sarepta and StrideBio Announce Multi-target Strategic Collaboration to Advance Novel Gene Therapies 11/7/19 Sarepta Therapeutics Announces Third Quarter 2019 Financial Results and Recent Corporate Developments 11/5/19 Sarepta Therapeutics to Present at the Credit Suisse 28th Annual Healthcare Conference 10/31/19 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 10/24/19 Sarepta Therapeutics to Announce Third Quarter 2019 Financial Results and Recent Corporate Developments on November 7, 2019 10/4/19 Sarepta Therapeutics Announces Positive Functional Results from the SRP-9003 (MYO-101) Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy 9/30/19 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 9/25/19 Sarepta Therapeutics to Announce 9-Month Functional Results from the SRP-9003 Gene Therapy Trial to Treat Limb-girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy 9/5/19 Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program Pagination First page « first Previous page ‹ previous … Page 3 Page 4 Page 5 Page 6 Current page 7 Page 8 Page 9 Page 10 Page 11 … Next page next › Last page last » Displaying 61 - 70 of 660 Toolkit Print Page | Email Alerts | RSS Feeds | Contacts
Press Releases Items Per Page 102550 News Category Business & FinancialCitizenshipEarningsMedia StatementProduct NewsRecognitionRegulatoryScience & Innovation Year None2021202020192018201720162015201420132012201120102009200820072006 Date Title 11/29/19 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 11/14/19 Sarepta and StrideBio Announce Multi-target Strategic Collaboration to Advance Novel Gene Therapies 11/7/19 Sarepta Therapeutics Announces Third Quarter 2019 Financial Results and Recent Corporate Developments 11/5/19 Sarepta Therapeutics to Present at the Credit Suisse 28th Annual Healthcare Conference 10/31/19 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 10/24/19 Sarepta Therapeutics to Announce Third Quarter 2019 Financial Results and Recent Corporate Developments on November 7, 2019 10/4/19 Sarepta Therapeutics Announces Positive Functional Results from the SRP-9003 (MYO-101) Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy 9/30/19 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 9/25/19 Sarepta Therapeutics to Announce 9-Month Functional Results from the SRP-9003 Gene Therapy Trial to Treat Limb-girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy 9/5/19 Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program Pagination First page « first Previous page ‹ previous … Page 3 Page 4 Page 5 Page 6 Current page 7 Page 8 Page 9 Page 10 Page 11 … Next page next › Last page last » Displaying 61 - 70 of 660